Network meta-analysis of 19 RCTs (17 analysed for the primary outcome; 2192 patients): vs placebo, topical silymarin (OR 0.08), diclofenac (0.23), 400-mg pyridoxine (0.28) and celecoxib (0.41) reduced grade 2+ chemotherapy hand-foot syndrome; mapisal increased overall risk.
Meta-analysisn = 2,192 patients
Baskarane et al. Preventing Hand-Foot Syndrome in Patients With Cancer: A Systematic Review and Network Meta-Analysis